Who is the new Chief Executive Officer at Sinaptica Therapeutics?

Sinaptica Therapeutics named Ken Mariash Chief Executive Officer, announced May 24, 2023.

Which similar companies made leadership changes around the same time?

HuidaGene Therapeutics (May 24, 2023), Phanes Therapeutics (May 30, 2023), Hinge Bio (May 31, 2023) and LumaBridge (May 31, 2023) also announced leadership changes within 45 days of Sinaptica Therapeutics.

Sinaptica Appoints Ken Mariash as Chief Executive Officer

PRIVATEMay 24, 2023

Position

Chief Executive Officer

Company

Sinaptica Therapeutics

Ken Mariash

ken@sinapticatx.com

CambridgeBiotechnologyHealth CareTherapeutics

Description

Sinaptica Therapeutics, Inc., a clinical-stage company leading the development of a new class of personalized neuromodulation therapeutics to treat Alzheimer’s and neurodegenerative diseases, announces the appointment of Ken Mariash Jr. as Chief Executive Officer. Mariash brings more than 25 years of life sciences leadership experience in strategy, corporate development, and marketing, both in medtech and biotech, at companies such as CSL Behring, Baxter BioScience, and Boston Scientific, including over a decade in the neuromodulation space.

Quick answer

Sinaptica Appoints Ken Mariash as Chief Executive Officer (May 24, 2023). Sinaptica Therapeutics is based in Cambridge, Maryland, United States.

Who is the new Chief Executive Officer at Sinaptica Therapeutics?: Sinaptica Therapeutics named Ken Mariash Chief Executive Officer, announced May 24, 2023.
What did Sinaptica Therapeutics announce on May 24, 2023?: Sinaptica Therapeutics, Inc., a clinical-stage company leading the development of a new class of personalized neuromodulation therapeutics to treat Alzheimer’s and neurodegenerative diseases, announces the appointment of Ken Mariash Jr. as Chief Executive Officer. Mariash brings more than 25 years of life sciences leadership experience in strategy, corporate development, and marketing, both in medtech and biotech,...
What does Sinaptica Therapeutics do?: Sinaptica Therapeutics™ is a Cambridge MA-based, clinical-stage company that has developed a personalized closed-loop neuromodulation therapy for Alzheimer’s Disease (AD).
Where is Sinaptica Therapeutics based?: Sinaptica Therapeutics is based in Cambridge, Maryland, United States.
Which similar companies made leadership changes around the same time?: HuidaGene Therapeutics (May 24, 2023), Phanes Therapeutics (May 30, 2023), Hinge Bio (May 31, 2023) and LumaBridge (May 31, 2023) also announced leadership changes within 45 days of Sinaptica Therapeutics.

Source: Fundz verified event record.

Other recent leadership changes in Therapeutics and Biotechnology

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

HuidaGene Therapeutics Appoints Alvin Luk as Chief Executive Officer (May 24, 2023)
Phanes Therapeutics announces the appointment of Rita Laeufle, MD, PhD, as Chief Medical Officer (May 30, 2023)
Juha Punnonen, M.D., Ph.D. Joins Hinge Bio as Chief Development Officer (May 31, 2023)
Todd Lehman Joins LumaBridge as Vice President and Head of Business Development (May 31, 2023)
Visgenx Appoints William Pedranti as Chief Executive Officer (June 5, 2023)
Chemomab Therapeutics Announces Executive Leadership Changes and Provides a Corporate Update (June 5, 2023)

Who to call at Sinaptica Therapeutics, and when

A new leader at Sinaptica Therapeutics brings new priorities and often new vendors. The first weeks are when they listen.

An alert the day Sinaptica Therapeutics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Sinaptica Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Sinaptica Therapeutics. With Fundz connected, it knows.

Watch Fundz in

See plan options

Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Sinaptica Therapeutics

Location

Cambridge, Maryland, United States

About

Sinaptica Therapeutics™ is a Cambridge MA-based, clinical-stage company that has developed a personalized closed-loop neuromodulation therapy for Alzheimer’s Disease (AD). The company was founded by two top clinical researchers in the field of noninvasive brain modulation for neurodegenerative disorders, together with support from biotech, digital health, and medical device industry executives. The company’s SinaptiStim™ System represents a totally new approach to treating AD by enhancing neuroplasticity via neurostimulation of key brain networks involved in memory, and has been granted FDA Breakthrough Designation based on unprecedented published Phase 2 sham-controlled data that achieved statistical significance on all four gold-standard cognitive & functional clinical endpoints. Sinaptica is building upon over a decade of research on innovative brain targeting methods, biophysical modeling, and noninvasive treatment protocols leveraging machine learning on proprietary datasets to create a foundational leap in personalized precision electromagnetic therapeutics. Based on highly significant published sham-controlled data, the company's neurostimulation device and integrated personalization engine has the potential to become one of the most clinically-effective treatments to reach Alzheimer’s patients in over two decades, and is protected by multiple pending patents.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Sinaptica Therapeutics changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Book a demo Explore plans